The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration–Dose Ratio on Death-censored Graft Survival
暂无分享,去创建一个
L. Rostaing | F. Stanke-Labesque | Johan Noble | B. Janbon | P. Malvezzi | G. Fiard | X. Fonrose | T. Jouve | T. Jouvé
[1] Reuter,et al. Fast Tac Metabolizers at Risk—It is Time for a C/D Ratio Calculation , 2019, Journal of clinical medicine.
[2] R. Tsonaka,et al. Pitfalls of linear regression for estimating slopes over time and how to avoid them by using linear mixed-effects models. , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[3] A. Åsberg,et al. High tacrolimus clearance – a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single‐center cohort study , 2018, Transplant International.
[4] F. Lemaitre,et al. Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation , 2018, Clinical Pharmacokinetics.
[5] D. Kuypers,et al. Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers , 2018, Drug Metabolism and Disposition.
[6] L. Pączek,et al. Evaluation of the Relationship Between Concentrations of Tacrolimus Metabolites, 13-O-Demethyl Tacrolimus and 15-O-Demethyl Tacrolimus, and Clinical and Biochemical Parameters in Kidney Transplant Recipients. , 2018, Transplantation proceedings.
[7] L. Rostaing,et al. Tailoring tacrolimus therapy in kidney transplantation , 2018, Expert review of clinical pharmacology.
[8] D. Brennan,et al. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] A. Åsberg,et al. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation , 2017, Transplantation.
[10] L. Rostaing,et al. New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients , 2017, Expert opinion on drug safety.
[11] L. Rostaing,et al. Reduction of Extended‐Release Tacrolimus Dose in Low‐Immunological‐Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor‐Specific Antibodies: A Randomized Study , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] S. Brouard,et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long‐Term Stable Kidney Transplant Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] S. Knight. Intrapatient variability in tacrolimus exposure – a useful tool for clinical practice? , 2016, Transplant international : official journal of the European Society for Organ Transplantation.
[14] M. Arias,et al. Within-Patient Variability in Tacrolimus Blood Levels Predicts Kidney Graft Loss and Donor-Specific Antibody Development , 2016, Transplantation.
[15] L. Pączek,et al. Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients. , 2016, Transplantation proceedings.
[16] V. Haufroid,et al. Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs , 2016, Therapeutic drug monitoring.
[17] C. O’Seaghdha,et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation , 2016, Journal of Nephrology.
[18] S. Aliño,et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies , 2014, The Pharmacogenomics Journal.
[19] H. Gerth,et al. The Tacrolimus Metabolism Rate Influences Renal Function after Kidney Transplantation , 2014, PloS one.
[20] S. Kim,et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. , 2014, Kidney international.
[21] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[22] W. Weimar,et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[23] P. Halloran,et al. Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] 橋本光男,et al. 腎移植におけるDSA(Donor specific antibody)陽性症例の検討 , 2008 .
[25] M. Guba,et al. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation , 2018 .
[26] P. Halloran,et al. Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.
[27] U. Christians,et al. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. , 1996, Clinical chemistry.